SCHEMBL2296448

SCHEMBL2296448

N[C@@H]1CCCC(F)(F)[C@@H]1NC(=O)c1nc(-c2cnn3ccccc23)c(Cl)s1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MARK3 P27448 7/20 0.67
JAK2 O60674 7/20 0.50
JAK1 P23458 7/20 0.50
JAK3 P52333 7/20 0.50
IRAK4 Q9NWZ3 3/20 0.50
CCNT1 O60563 3/20 0.50
TYK2 P29597 3/20 0.50
CDK9 P50750 3/20 0.50
SYK P43405 2/20 0.50
CDK2 P24941 2/20 0.50
SGK1 O00141 1/20 0.50
CHEK1 O14757 1/20 0.50
IKBKB O14920 1/20 0.50
MAPK13 O15264 1/20 0.50
PDPK1 O15530 1/20 0.50
NUAK1 O60285 1/20 0.50
ROCK2 O75116 1/20 0.50
CHEK2 O96017 1/20 0.50
ABL1 P00519 1/20 0.50
RAF1 P04049 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2293346 1.00 MARK3 (0.67) MARK3JAK2JAK1JAK3IRAK4
SCHEMBL2292964 0.91 MARK3 (0.55) MARK3JAK2JAK1JAK3IRAK4
SCHEMBL15104015 0.90 MARK3 (0.58) MARK3JAK2JAK1JAK3IRAK4
SCHEMBL2292831 0.90 MARK3 (0.56) MARK3JAK2JAK1JAK3IRAK4
SCHEMBL2288840 0.90 MARK3 (0.58) MARK3JAK2JAK1JAK3IRAK4
SCHEMBL2290682 0.90 MARK3 (0.60) MARK3JAK2JAK1JAK3IRAK4
SCHEMBL12379683 0.89 MARK3 (0.55) MARK3JAK2JAK1JAK3IRAK4
SCHEMBL12418687 0.89 MARK3 (0.55) MARK3JAK2JAK1JAK3IRAK4
SCHEMBL15108349 0.89 MARK3 (0.55) MARK3JAK2JAK1JAK3IRAK4
SCHEMBL2291973 0.89 MARK3 (0.55) MARK3JAK2JAK1JAK3IRAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8518911-B2 Pyrazolo[1,5-a]pyridines as MARK inhibitors MERCK SHARP & DOHME CORP. (US) 2013-08-27 US disclosed
US-8518911-B2 Pyrazolo[1,5-a]pyridines as MARK inhibitors MERCK SHARP & DOHME CORP. (US) 2013-08-27 US disclosed
EP-2320737-B1 PYRAZOLO-[1,5-A]-PYRIDINES AS MARK INHIBITORS MERCK SHARP & DOHME (US) 2013-07-17 EP disclosed
EP-2320737-B1 PYRAZOLO-[1,5-A]-PYRIDINES AS MARK INHIBITORS MERCK SHARP & DOHME (US) 2013-07-17 EP disclosed
US-20110195933-A1 PYRAZOLO[1,5-A]PYRIDINES AS MARK INHIBITORS MERCK SHARP & DOHME LLC 2011-08-11 US disclosed
US-20110195933-A1 PYRAZOLO[1,5-A]PYRIDINES AS MARK INHIBITORS MERCK SHARP & DOHME LLC 2011-08-11 US disclosed
WO-2010017046-A1 PYRAZOLO[1,5-A]PYRIDINES AS MARK INHIBITORS MERCK & CO., INC. (US) 2010-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110195933-A1 PYRAZOLO[1,5-A]PYRIDINES AS MARK INHIBITORS MARK3, MARK4, MARK1 MARK3 1/4885JAK2 1240/4885JAK1 521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.